Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00015002
Other study ID # NICHD-0801
Secondary ID HD21410HD27869HD
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 2000
Est. completion date March 2007

Study information

Verified date March 2022
Source The George Washington University Biostatistics Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A course of steroids given to a mother who is in labor with a premature fetus will reduce the risk of the premature infant dying or having serious complications. This trial will test whether more than one course of antenatal steroids is more beneficial or risky to the infant than a single course.


Description:

After the NICHD Consensus Development Conference in 1994, the antenatal administration of antenatal corticosteroids (betamethasone or dexamethasone) for prevention of death and the serious morbidities associated with preterm birth has become an accepted standard in American obstetric practice. Studies have shown that maximum beneficial effect occurs when the fetus is delivered within 7 days of antenatal steroid administration. The efficacy and safety of a single course of corticosteroids has been substantiated but it is unknown whether repetitive dosing has similar efficacy or what the maternal, fetal and neonatal risks are. Repeat courses of steroids are often administered. Two popular regimens exist for the patient who remains undelivered more than one week after initial therapy but who remains at risk for preterm birth. In one, steroids are repeated weekly until 34 weeks gestation, while in the other, steroids are only given once. This multicenter trial is testing the safety and efficacy of weekly administration of antenatal steroids. Twenty four hundred women < 32.0 weeks gestation who are at risk for spontaneous preterm delivery and remain pregnant at least seven days after an initial course of corticosteroids are being randomized to either weekly courses of masked study drug (betamethasone or placebo) for 4 weeks or delivery, whichever comes first. Patients are asked about side effects at the weekly visits and samples of maternal blood at randomization and delivery are collected. Cord blood and placentas are also collected. Cranial ultrasounds are done on all neonates. On a subgroup of patients, an adrenocorticotrophic hormone (ACTH) stimulation test is being performed and an auditory brainstem response (ABR) performed. All infants attend a follow-up visit at 18 to 22 months corrected age where certified examiners, masked to study group assignment, collect physical and neurological data. The Bayley Scales of Infant Development will also be administered. A subgroup of infants will be seen at 36 months to administer the Intelligence scale from the McCarthy Scales of Children's Abilities.


Recruitment information / eligibility

Status Terminated
Enrollment 486
Est. completion date March 2007
Est. primary completion date May 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion criteria: - Pregnant - Gestational age > 23.0 wks and < 31.6 wks - Singleton or twin pregnancy - Intact membranes - At-risk for spontaneous preterm delivery - Received full course of corticosteroids within the previous 7 days Exclusion criteria: - Diagnosis of fetal lung maturity - Chorioamnionitis - Non-reassuring fetal testing - Known major fetal anomaly - Corticosteroid therapy, other than qualifying course - Insulin dependent diabetes - Active preterm labor at the time of randomization - Delivery intended outside center - Participation in any intervention study which influences neonatal morbidity or mortality - Previous participation in this trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Betamethasone
coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the "Course"). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first.

Locations

Country Name City State
United States University of Alabama Birmingham Alabama
United States University of North Carolina Chapel Hill North Carolina
United States Northwestern University-Prentice Hospital Chicago Illinois
United States University of Chicago Chicago Illinois
United States University of Cincinnati Cincinnati Ohio
United States Case Western Reserve-Metrohealth Cleveland Ohio
United States Dept of OB/GYN, Ohio State University Columbus Ohio
United States Dept of OB/GYN, Southwestern Medical Center, University of Texas Dallas Texas
United States Dept of OB/GYN, Hutzel Hospital Detroit Michigan
United States University of Texas-Houston Houston Texas
United States University of Tennessee Memphis Tennessee
United States University of Miami Miami Florida
United States Columbia University New York New York
United States MCP Hahnamann Philadelphia Pennsylvania
United States Dept of OB/GYN, Magee-Womens Hospital Pittsburgh Pennsylvania
United States Brown University -Women and Infants Hospital Providence Rhode Island
United States University of Utah Medical Center Salt Lake City Utah
United States University of Texas - San Antonio San Antonio Texas
United States Forsyth Memorial Hospital, Wake Forest University School of Medicine Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
The George Washington University Biostatistics Center Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

References & Publications (12)

Carroll MA, Vidaeff AC, Mele L, Wapner RJ, Mercer B, Peaceman AM, Sorokin Y, Dudley DJ, Spong CY, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Thorp JM, Moawad A, O'Sullivan MJ, Carpenter MW, Rouse DJ, Sibai B; National Institute of Child Health and Huma — View Citation

Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol. 1995 Jul;173(1):322-35. — View Citation

Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol. 1981 Oct 1;141(3):276-87. — View Citation

Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA. 1995 Feb 1;273(5):413-8. Review. — View Citation

Fonseca L, Ramin SM, Mele L, Wapner RJ, Johnson F, Peaceman AM, Sorokin Y, Dudley DJ, Spong CY, Leveno KJ, Caritis SN, Miodovnik M, Mercer B, Thorp JM, O'Sullivan MJ, Carpenter MW, Rouse DJ, Sibai B; Eunice Kennedy Shriver National Institute of Child Heal — View Citation

French NP, Hagan R, Evans SF, Godfrey M, Newnham JP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):114-21. — View Citation

Gamsu HR, Mullinger BM, Donnai P, Dash CH. Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. Br J Obstet Gynaecol. 1989 Apr;96(4):401-10. — View Citation

Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972 Oct;50(4):515-25. — View Citation

Sawady J, Mercer BM, Wapner RJ, Zhao Y, Sorokin Y, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Thorp JM, Ramin S, Carpenter MW, Rouse DJ; National Institute of Child Health and Human Development Maternal Feta — View Citation

Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Malone F, Caritis SN, Mercer B, Harper M, Rouse DJ, Thorp JM, Ramin S, Carpenter MW, Gabbe SG; National Institute of Child Health and Human Development Maternal-Fetal Me — View Citation

Wapner RJ, Sorokin Y, Thom EA, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Mercer B, Thorp JM, Moawad A, O'Sullivan MJ, Ramin S, Carpenter MW, Rouse DJ, Sibai B, Gabbe SG; National Institute of Child Health a — View Citation

Wright LL. Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in very low birthweight infants. In: National Institute of Child Health and Development (US). Report on the Consensus Development Conference on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes; 1994 Feb 28-Mar 2; Bethesda, (MD): The Institute; 1994 Nov. P. 47-8. (NIH Publication; no. 95-3784).

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Composite outcome: including neonatal mortality/stillbirth, severe RDS, chronic lung disease, grade III/IV IVH, PVL
Secondary Neonatal morbidity
Secondary Maternal morbidity
Secondary Neonatal Growth parameters
Secondary Infant neurological parameters
See also
  Status Clinical Trial Phase
Completed NCT03922087 - No-worry Baby Project